Skip to main content Skip to footer
HomeHome
 
  • Homepage
  • Searching for patents

    Patent knowledge

    Access our patent databases and search tools.

    Go to overview 

    • Overview
    • Technical information
      • Overview
      • Espacenet - patent search
      • European Publication Server
      • EP full-text search
    • Legal information
      • Overview
      • European Patent Register
      • European Patent Bulletin
      • European Case Law Identifier sitemap
      • Third-party observations
    • Business information
      • Overview
      • PATSTAT
      • IPscore
      • Technology insight reports
    • Data
      • Overview
      • Technology Intelligence Platform
      • Linked open EP data
      • Bulk data sets
      • Web services
      • Coverage, codes and statistics
    • Technology platforms
      • Overview
      • Plastics in transition
      • Water innovation
      • Space innovation
      • Technologies combatting cancer
      • Firefighting technologies
      • Clean energy technologies
      • Fighting coronavirus
    • Helpful resources
      • Overview
      • First time here?
      • Asian patent information
      • Patent information centres
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge
    Image
    Plastics in Transition

    Technology insight report on plastic waste management

  • Applying for a patent

    Applying for a patent

    Practical information on filing and grant procedures.

    Go to overview 

    • Overview
    • European route
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
      • Appeals
      • Unitary Patent & Unified Patent Court
      • National validation
      • Request for extension/validation
    • International route (PCT)
      • Overview
      • Euro-PCT Guide – PCT procedure at the EPO
      • EPO decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
      • Training and events
    • National route
    • Find a professional representative
    • MyEPO services
      • Overview
      • Understand our services
      • Get access
      • File with us
      • Interact with us on your files
      • Online Filing & fee payment outages
    • Forms
      • Overview
      • Request for examination
    • Fees
      • Overview
      • European fees (EPC)
      • International fees (PCT)
      • Unitary Patent fees (UP)
      • Fee payment and refunds
      • Warning

    UP

    Find out how the Unitary Patent can enhance your IP strategy

  • Law & practice

    Law & practice

    European patent law, the Official Journal and other legal texts.

    Go to overview 

    • Overview
    • Legal texts
      • Overview
      • European Patent Convention
      • Official Journal
      • Guidelines
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
      • Unitary patent system
      • National measures relating to the Unitary Patent
    • Court practices
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives
    Image
    Law and practice scales 720x237

    Keep up with key aspects of selected BoA decisions with our monthly "Abstracts of decisions”

  • News & events

    News & events

    Our latest news, podcasts and events, including the European Inventor Award.

    Go to overview 

     

    • Overview
    • News
    • Events
    • European Inventor Award
      • Overview
      • The meaning of tomorrow
      • About the award
      • Categories and prizes
      • Meet the finalists
      • Nominations
      • European Inventor Network
      • The 2024 event
    • Young Inventor Prize
      • Overview
      • About the prize
      • Nominations
      • The jury
      • The world, reimagined
    • Press centre
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • Innovation and patenting in focus
      • Overview
      • Water-related technologies
      • CodeFest
      • Green tech in focus
      • Research institutes
      • Women inventors
      • Lifestyle
      • Space and satellites
      • The future of medicine
      • Materials science
      • Mobile communications
      • Biotechnology
      • Patent classification
      • Digital technologies
      • The future of manufacturing
      • Books by EPO experts
    • "Talk innovation" podcast

    Podcast

    From ideas to inventions: tune into our podcast for the latest in tech and IP

  • Learning

    Learning

    The European Patent Academy – the point of access to your learning

    Go to overview 

    • Overview
    • Learning activities and paths
      • Overview
      • Learning activities
      • Learning paths
    • EQE and EPAC
      • Overview
      • EQE - European qualifying examination
      • EPAC - European patent administration certification
      • CSP – Candidate Support Programme
    • Learning resources by area of interest
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
    • Learning resources by profile
      • Overview
      • Business and IP managers
      • EQE and EPAC Candidates
      • Judges, lawyers and prosecutors
      • National offices and IP authorities
      • Patent attorneys and paralegals
      • Universities, research centres and technology transfer centres (TTOs)
    Image
    Patent Academy catalogue

    Have a look at the extensive range of learning opportunities in the European Patent Academy training catalogue

  • About us

    About us

    Find out more about our work, values, history and vision

    Go to overview 

    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Overview
      • Official celebrations
      • Member states’ video statements
      • 50 Leading Tech Voices
      • Athens Marathon
      • Kids’ collaborative art competition
    • Legal foundations and member states
      • Overview
      • Legal foundations
      • Member states of the European Patent Organisation
      • Extension states
      • Validation states
    • Administrative Council and subsidiary bodies
      • Overview
      • Communiqués
      • Calendar
      • Documents and publications
      • Administrative Council
    • Principles & strategy
      • Overview
      • Our mission, vision, values and corporate policy
      • Strategic Plan 2028
      • Towards a New Normal
    • Leadership & management
      • Overview
      • President António Campinos
      • Management Advisory Committee
    • Sustainability at the EPO
      • Overview
      • Environmental
      • Social
      • Governance and Financial sustainability
    • Services & activities
      • Overview
      • Our services & structure
      • Quality
      • Consulting our users
      • European and international co-operation
      • European Patent Academy
      • Chief Economist
      • Ombuds Office
      • Reporting wrongdoing
    • Observatory on Patents and Technology
      • Overview
      • Innovation actors
      • Policy and funding
      • Tools
      • About the Observatory
    • Procurement
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • Sustainable Procurement Policy
      • About eTendering and electronic signatures
      • Procurement portal
      • Invoicing
      • General conditions
      • Archived tenders
    • Transparency portal
      • Overview
      • General
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
    • Statistics and trends
      • Overview
      • Statistics & Trends Centre
      • Patent Index 2024
      • EPO Data Hub
      • Clarification on data sources
    • History
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s
    • Art collection
      • Overview
      • The collection
      • Let's talk about art
      • Artists
      • Media library
      • What's on
      • Publications
      • Contact
      • Culture Space A&T 5-10
      • "Long Night"
    Image
    Patent Index 2024 keyvisual showing brightly lit up data chip, tinted in purple, bright blue

    Track the latest tech trends with our Patent Index

 
Website
cancel
en de fr
  • Language selection
  • English
  • Deutsch
  • Français
Main navigation
  • Homepage
    • Go back
    • New to patents
  • New to patents
    • Go back
    • Your business and patents
    • Why do we have patents?
    • What's your big idea?
    • Are you ready?
    • What to expect
    • How to apply for a patent
    • Is it patentable?
    • Are you first?
    • Patent quiz
    • Unitary patent video
  • Searching for patents
    • Go back
    • Overview
    • Technical information
      • Go back
      • Overview
      • Espacenet - patent search
        • Go back
        • Overview
        • National patent office databases
        • Global Patent Index (GPI)
        • Release notes
      • European Publication Server
        • Go back
        • Overview
        • Release notes
        • Cross-reference index for Euro-PCT applications
        • EP authority file
        • Help
      • EP full-text search
    • Legal information
      • Go back
      • Overview
      • European Patent Register
        • Go back
        • Overview
        • Release notes archive
        • Register documentation
          • Go back
          • Overview
          • Deep link data coverage
          • Federated Register
          • Register events
      • European Patent Bulletin
        • Go back
        • Overview
        • Download Bulletin
        • EP Bulletin search
        • Help
      • European Case Law Identifier sitemap
      • Third-party observations
    • Business information
      • Go back
      • Overview
      • PATSTAT
      • IPscore
        • Go back
        • Release notes
      • Technology insight reports
    • Data
      • Go back
      • Overview
      • Technology Intelligence Platform
      • Linked open EP data
      • Bulk data sets
        • Go back
        • Overview
        • Manuals
        • Sequence listings
        • National full-text data
        • European Patent Register data
        • EPO worldwide bibliographic data (DOCDB)
        • EP full-text data
        • EPO worldwide legal event data (INPADOC)
        • EP bibliographic data (EBD)
        • Boards of Appeal decisions
      • Web services
        • Go back
        • Overview
        • Open Patent Services (OPS)
        • European Publication Server web service
      • Coverage, codes and statistics
        • Go back
        • Weekly updates
        • Updated regularly
    • Technology platforms
      • Go back
      • Overview
      • Plastics in transition
        • Go back
        • Overview
        • Plastics waste recovery
        • Plastics waste recycling
        • Alternative plastics
      • Innovation in water technologies
        • Go back
        • Overview
        • Clean water
        • Protection from water
      • Space innovation
        • Go back
        • Overview
        • Cosmonautics
        • Space observation
      • Technologies combatting cancer
        • Go back
        • Overview
        • Prevention and early detection
        • Diagnostics
        • Therapies
        • Wellbeing and aftercare
      • Firefighting technologies
        • Go back
        • Overview
        • Detection and prevention of fires
        • Fire extinguishing
        • Protective equipment
        • Post-fire restoration
      • Clean energy technologies
        • Go back
        • Overview
        • Renewable energy
        • Carbon-intensive industries
        • Energy storage and other enabling technologies
      • Fighting coronavirus
        • Go back
        • Overview
        • Vaccines and therapeutics
          • Go back
          • Overview
          • Vaccines
          • Overview of candidate therapies for COVID-19
          • Candidate antiviral and symptomatic therapeutics
          • Nucleic acids and antibodies to fight coronavirus
        • Diagnostics and analytics
          • Go back
          • Overview
          • Protein and nucleic acid assays
          • Analytical protocols
        • Informatics
          • Go back
          • Overview
          • Bioinformatics
          • Healthcare informatics
        • Technologies for the new normal
          • Go back
          • Overview
          • Devices, materials and equipment
          • Procedures, actions and activities
          • Digital technologies
        • Inventors against coronavirus
    • Helpful resources
      • Go back
      • Overview
      • First time here?
        • Go back
        • Overview
        • Basic definitions
        • Patent classification
          • Go back
          • Overview
          • Cooperative Patent Classification (CPC)
        • Patent families
          • Go back
          • Overview
          • DOCDB simple patent family
          • INPADOC extended patent family
        • Legal event data
          • Go back
          • Overview
          • INPADOC classification scheme
      • Asian patent information
        • Go back
        • Overview
        • China (CN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Chinese Taipei (TW)
          • Go back
          • Overview
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • India (IN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
        • Japan (JP)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Korea (KR)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Russian Federation (RU)
          • Go back
          • Overview
          • Facts and figures
          • Numbering system
          • Searching in databases
        • Useful links
      • Patent information centres (PATLIB)
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge
  • Applying for a patent
    • Go back
    • Overview
    • European route
      • Go back
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
        • Go back
        • Oral proceedings calendar
          • Go back
          • Calendar
          • Public access to appeal proceedings
          • Public access to opposition proceedings
          • Technical guidelines
      • Appeals
      • Unitary Patent & Unified Patent Court
        • Go back
        • Overview
        • Unitary Patent
          • Go back
          • Overview
          • Legal framework
          • Main features
          • Applying for a Unitary Patent
          • Cost of a Unitary Patent
          • Translation and compensation
          • Start date
          • Introductory brochures
        • Unified Patent Court
      • National validation
      • Extension/validation request
    • International route
      • Go back
      • Overview
      • Euro-PCT Guide
      • Entry into the European phase
      • Decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
        • Go back
        • Patent Prosecution Highway (PPH) programme outline
      • Training and events
    • National route
    • MyEPO services
      • Go back
      • Overview
      • Understand our services
        • Go back
        • Overview
        • Exchange data with us using an API
          • Go back
          • Release notes
      • Get access
        • Go back
        • Overview
        • Release notes
      • File with us
        • Go back
        • Overview
        • What if our online filing services are down?
        • Release notes
      • Interact with us on your files
        • Go back
        • Release notes
      • Online Filing & fee payment outages
    • Fees
      • Go back
      • Overview
      • European fees (EPC)
        • Go back
        • Overview
        • Decisions and notices
      • International fees (PCT)
        • Go back
        • Reduction in fees
        • Fees for international applications
        • Decisions and notices
        • Overview
      • Unitary Patent fees (UP)
        • Go back
        • Overview
        • Decisions and notices
      • Fee payment and refunds
        • Go back
        • Overview
        • Payment methods
        • Getting started
        • FAQs and other documentation
        • Technical information for batch payments
        • Decisions and notices
        • Release notes
      • Warning
    • Forms
      • Go back
      • Overview
      • Request for examination
    • Find a professional representative
  • Law & practice
    • Go back
    • Overview
    • Legal texts
      • Go back
      • Overview
      • European Patent Convention
        • Go back
        • Overview
        • Archive
          • Go back
          • Overview
          • Documentation on the EPC revision 2000
            • Go back
            • Overview
            • Diplomatic Conference for the revision of the EPC
            • Travaux préparatoires
            • New text
            • Transitional provisions
            • Implementing regulations to the EPC 2000
            • Rules relating to Fees
            • Ratifications and accessions
          • Travaux Préparatoires EPC 1973
      • Official Journal
      • Guidelines
        • Go back
        • Overview
        • EPC Guidelines
        • PCT-EPO Guidelines
        • Unitary Patent Guidelines
        • Guidelines revision cycle
        • Consultation results
        • Summary of user responses
        • Archive
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
        • Go back
        • Overview
        • Archive
      • Unitary Patent system
        • Go back
        • Travaux préparatoires to UP and UPC
      • National measures relating to the Unitary Patent 
    • Court practices
      • Go back
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Go back
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Go back
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives
  • News & events
    • Go back
    • Overview
    • News
    • Events
    • European Inventor Award
      • Go back
      • Overview
      • The meaning of tomorrow
      • About the award
      • Categories and prizes
      • Meet the inventors
      • Nominations
      • European Inventor Network
        • Go back
        • 2024 activities
        • 2025 activities
        • Rules and criteria
        • FAQ
      • The 2024 event
    • Young Inventors Prize
      • Go back
      • Overview
      • About the prize
      • Nominations
      • The jury
      • The world, reimagined
      • The 2025 event
    • Press centre
      • Go back
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
        • Go back
        • Overview
        • European Patent Office
        • Q&A on patents related to coronavirus
        • Q&A on plant patents
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • In focus
      • Go back
      • Overview
      • Water-related technologies
      • CodeFest
        • Go back
        • CodeFest Spring 2025 on classifying patent data for sustainable development
        • Overview
        • CodeFest 2024 on generative AI
        • CodeFest 2023 on Green Plastics
      • Green tech in focus
        • Go back
        • Overview
        • About green tech
        • Renewable energies
        • Energy transition technologies
        • Building a greener future
      • Research institutes
      • Women inventors
      • Lifestyle
      • Space and satellites
        • Go back
        • Overview
        • Patents and space technologies
      • Healthcare
        • Go back
        • Overview
        • Medical technologies and cancer
        • Personalised medicine
      • Materials science
        • Go back
        • Overview
        • Nanotechnology
      • Mobile communications
      • Biotechnology
        • Go back
        • Overview
        • Red, white or green
        • The role of the EPO
        • What is patentable?
        • Biotech inventors
      • Classification
        • Go back
        • Overview
        • Nanotechnology
        • Climate change mitigation technologies
          • Go back
          • Overview
          • External partners
          • Updates on Y02 and Y04S
      • Digital technologies
        • Go back
        • Overview
        • About ICT
        • Hardware and software
        • Artificial intelligence
        • Fourth Industrial Revolution
      • Additive manufacturing
        • Go back
        • Overview
        • About AM
        • AM innovation
      • Books by EPO experts
    • Podcast
  • Learning
    • Go back
    • Overview
    • Learning activities and paths
      • Go back
      • Overview
      • Learning activities: types and formats
      • Learning paths
    • EQE and EPAC
      • Go back
      • Overview
      • EQE - European Qualifying Examination
        • Go back
        • Overview
        • Compendium
          • Go back
          • Overview
          • Paper F
          • Paper A
          • Paper B
          • Paper C
          • Paper D
          • Pre-examination
        • Candidates successful in the European qualifying examination
        • Archive
      • EPAC - European patent administration certification
      • CSP – Candidate Support Programme
    • Learning resources by area of interest
      • Go back
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
    • Learning resources by profile
      • Go back
      • Overview
      • Business and IP managers
        • Go back
        • Overview
        • Innovation case studies
          • Go back
          • Overview
          • SME case studies
          • Technology transfer case studies
          • High-growth technology case studies
        • Inventor's handbook
          • Go back
          • Overview
          • Introduction
          • Disclosure and confidentiality
          • Novelty and prior art
          • Competition and market potential
          • Assessing the risk ahead
          • Proving the invention
          • Protecting your idea
          • Building a team and seeking funding
          • Business planning
          • Finding and approaching companies
          • Dealing with companies
        • Best of search matters
          • Go back
          • Overview
          • Tools and databases
          • EPO procedures and initiatives
          • Search strategies
          • Challenges and specific topics
        • Support for high-growth technology businesses
          • Go back
          • Overview
          • Business decision-makers
          • IP professionals
          • Stakeholders of the Innovation Ecosystem
      • EQE and EPAC Candidates
        • Go back
        • Overview
        • Paper F brain-teasers
        • Daily D questions
        • European qualifying examination - Guide for preparation
        • EPAC
      • Judges, lawyers and prosecutors
        • Go back
        • Overview
        • Compulsory licensing in Europe
        • The jurisdiction of European courts in patent disputes
      • National offices and IP authorities
        • Go back
        • Overview
        • Learning material for examiners of national officers
        • Learning material for formalities officers and paralegals
      • Patent attorneys and paralegals
      • Universities, research centres and TTOs
        • Go back
        • Overview
        • Modular IP Education Framework (MIPEF)
        • Pan-European Seal Young Professionals Programme
          • Go back
          • Overview
          • For students
          • For universities
            • Go back
            • Overview
            • IP education resources
            • University memberships
          • Our young professionals
          • Professional development plan
        • Academic Research Programme
          • Go back
          • Overview
          • Completed research projects
          • Current research projects
        • IP Teaching Kit
          • Go back
          • Overview
          • Download modules
        • Intellectual property course design manual
        • PATLIB Knowledge Transfer to Africa
          • Go back
          • The PATLIB Knowledge Transfer to Africa initiative (KT2A)
          • KT2A core activities
          • Success story: Malawi University of Science and Technology and PATLIB Birmingham
  • About us
    • Go back
    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Go back
      • Official celebrations
      • Overview
      • Member states’ video statements
        • Go back
        • Albania
        • Austria
        • Belgium
        • Bulgaria
        • Croatia
        • Cyprus
        • Czech Republic
        • Denmark
        • Estonia
        • Finland
        • France
        • Germany
        • Greece
        • Hungary
        • Iceland
        • Ireland
        • Italy
        • Latvia
        • Liechtenstein
        • Lithuania
        • Luxembourg
        • Malta
        • Monaco
        • Montenegro
        • Netherlands
        • North Macedonia
        • Norway
        • Poland
        • Portugal
        • Romania
        • San Marino
        • Serbia
        • Slovakia
        • Slovenia
        • Spain
        • Sweden
        • Switzerland
        • Türkiye
        • United Kingdom
      • 50 Leading Tech Voices
      • Athens Marathon
      • Kids’ collaborative art competition
    • Legal foundations and member states
      • Go back
      • Overview
      • Legal foundations
      • Member states
        • Go back
        • Overview
        • Member states by date of accession
      • Extension states
      • Validation states
    • Administrative Council and subsidiary bodies
      • Go back
      • Overview
      • Communiqués
        • Go back
        • 2024
        • Overview
        • 2023
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
        • 2017
        • 2016
        • 2015
        • 2014
        • 2013
      • Calendar
      • Documents and publications
        • Go back
        • Overview
        • Select Committee documents
      • Administrative Council
        • Go back
        • Overview
        • Composition
        • Representatives
        • Rules of Procedure
        • Board of Auditors
        • Secretariat
        • Council bodies
    • Principles & strategy
      • Go back
      • Overview
      • Mission, vision, values & corporate policy
      • Strategic Plan 2028
        • Go back
        • Driver 1: People
        • Driver 2: Technologies
        • Driver 3: High-quality, timely products and services
        • Driver 4: Partnerships
        • Driver 5: Financial sustainability
      • Towards a New Normal
      • Data protection & privacy notice
    • Leadership & management
      • Go back
      • Overview
      • About the President
      • Management Advisory Committee
    • Sustainability at the EPO
      • Go back
      • Overview
      • Environmental
        • Go back
        • Overview
        • Inspiring environmental inventions
      • Social
        • Go back
        • Overview
        • Inspiring social inventions
      • Governance and Financial sustainability
    • Procurement
      • Go back
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • Dynamic Purchasing System (DPS) publications
      • Sustainable Procurement Policy
      • About eTendering
      • Invoicing
      • Procurement portal
        • Go back
        • Overview
        • e-Signing contracts
      • General conditions
      • Archived tenders
    • Services & activities
      • Go back
      • Overview
      • Our services & structure
      • Quality
        • Go back
        • Overview
        • Foundations
          • Go back
          • Overview
          • European Patent Convention
          • Guidelines for examination
          • Our staff
        • Enabling quality
          • Go back
          • Overview
          • Prior art
          • Classification
          • Tools
          • Processes
        • Products & services
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
          • Continuous improvement
        • Quality through networking
          • Go back
          • Overview
          • User engagement
          • Co-operation
          • User satisfaction survey
          • Stakeholder Quality Assurance Panels
        • Patent Quality Charter
        • Quality Action Plan
        • Quality dashboard
        • Statistics
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
        • Integrated management at the EPO
      • Consulting our users
        • Go back
        • Overview
        • Standing Advisory Committee before the EPO (SACEPO)
          • Go back
          • Overview
          • Objectives
          • SACEPO and its working parties
          • Meetings
          • Single Access Portal – SACEPO Area
        • Surveys
          • Go back
          • Overview
          • Detailed methodology
          • Search services
          • Examination services, final actions and publication
          • Opposition services
          • Formalities services
          • Customer services
          • Filing services
          • Key Account Management (KAM)
          • Website
          • Archive
      • Our user service charter
      • European and international co-operation
        • Go back
        • Overview
        • Co-operation with member states
          • Go back
          • Overview
        • Bilateral co-operation with non-member states
          • Go back
          • Overview
          • Validation system
          • Reinforced Partnership programme
        • Multilateral international co-operation with IP offices and organisations
        • Co-operation with international organisations outside the IP system
      • European Patent Academy
        • Go back
        • Overview
        • Partners
      • Chief Economist
        • Go back
        • Overview
        • Economic studies
      • Ombuds Office
      • Reporting wrongdoing
    • Observatory on Patents and Technology
      • Go back
      • Overview
      • Innovation against cancer
      • Innovation actors
        • Go back
        • Overview
        • Startups and SMEs
      • Policy and funding
        • Go back
        • Overview
        • Financing innovation programme
          • Go back
          • Overview
          • Our studies on the financing of innovation
          • EPO initiatives for patent applicants
          • Financial support for innovators in Europe
        • Patents and standards
          • Go back
          • Overview
          • Publications
          • Patent standards explorer
      • Tools
        • Go back
        • Overview
        • Deep Tech Finder
      • About the Observatory
        • Go back
        • Overview
        • Work plan
    • Transparency portal
      • Go back
      • Overview
      • General
        • Go back
        • Overview
        • Annual Review 2023
          • Go back
          • Overview
          • Foreword
          • Executive summary
          • 50 years of the EPC
          • Strategic key performance indicators
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
        • Annual Review 2022
          • Go back
          • Overview
          • Foreword
          • Executive summary
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
    • Statistics and trends
      • Go back
      • Overview
      • Statistics & Trends Centre
      • Patent Index 2024
        • Go back
        • Insight into computer technology and AI
        • Insight into clean energy technologies
        • Statistics and indicators
          • Go back
          • European patent applications
            • Go back
            • Key trend
            • Origin
            • Top 10 technical fields
              • Go back
              • Computer technology
              • Electrical machinery, apparatus, energy
              • Digital communication
              • Medical technology
              • Transport
              • Measurement
              • Biotechnology
              • Pharmaceuticals
              • Other special machines
              • Organic fine chemistry
            • All technical fields
          • Applicants
            • Go back
            • Top 50
            • Categories
            • Women inventors
          • Granted patents
            • Go back
            • Key trend
            • Origin
            • Designations
      • Data to download
      • EPO Data Hub
      • Clarification on data sources
    • History
      • Go back
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s
    • Art collection
      • Go back
      • Overview
      • The collection
      • Let's talk about art
      • Artists
      • Media library
      • What's on
      • Publications
      • Contact
      • Culture Space A&T 5-10
        • Go back
        • Catalyst lab & Deep vision
          • Go back
          • Irene Sauter (DE)
          • AVPD (DK)
          • Jan Robert Leegte (NL)
          • Jānis Dzirnieks (LV) #1
          • Jānis Dzirnieks (LV) #2
          • Péter Szalay (HU)
          • Thomas Feuerstein (AT)
          • Tom Burr (US)
          • Wolfgang Tillmans (DE)
          • TerraPort
          • Unfinished Sculpture - Captives #1
          • Deep vision – immersive exhibition
          • Previous exhibitions
        • The European Patent Journey
        • Sustaining life. Art in the climate emergency
        • Next generation statements
        • Open storage
        • Cosmic bar
      • "Long Night"
  • Boards of Appeal
    • Go back
    • Overview
    • Decisions of the Boards of Appeal
      • Go back
      • Overview
      • Recent decisions
      • Selected decisions
    • Information from the Boards of Appeal
    • Procedure
    • Oral proceedings
    • About the Boards of Appeal
      • Go back
      • Overview
      • President of the Boards of Appeal
      • Enlarged Board of Appeal
        • Go back
        • Overview
        • Pending referrals (Art. 112 EPC)
        • Decisions sorted by number (Art. 112 EPC)
        • Pending petitions for review (Art. 112a EPC)
        • Decisions on petitions for review (Art. 112a EPC)
      • Technical Boards of Appeal
      • Legal Board of Appeal
      • Disciplinary Board of Appeal
      • Presidium
        • Go back
        • Overview
    • Code of Conduct
    • Business distribution scheme
      • Go back
      • Overview
      • Technical boards of appeal by IPC in 2025
      • Archive
    • Annual list of cases
    • Communications
    • Annual reports
      • Go back
      • Overview
    • Publications
      • Go back
      • Abstracts of decisions
    • Case Law of the Boards of Appeal
      • Go back
      • Overview
      • Archive
  • Service & support
    • Go back
    • Overview
    • Website updates
    • Availability of online services
      • Go back
      • Overview
    • FAQ
      • Go back
      • Overview
    • Publications
    • Ordering
      • Go back
      • Overview
      • Patent Knowledge Products and Services
      • Terms and conditions
        • Go back
        • Overview
        • Patent information products
        • Bulk data sets
        • Open Patent Services (OPS)
        • Fair use charter
    • Procedural communications
    • Useful links
      • Go back
      • Overview
      • Patent offices of member states
      • Other patent offices
      • Directories of patent attorneys
      • Patent databases, registers and gazettes
      • Disclaimer
    • Contact us
      • Go back
      • Overview
      • Filing options
      • Locations
    • Subscription centre
      • Go back
      • Overview
      • Subscribe
      • Change preferences
      • Unsubscribe
    • Official holidays
    • Glossary
    • RSS feeds
Board of Appeals
Decisions

Recent decisions

Overview
  • 2025 decisions
  • 2024 decisions
  • 2023 decisions
  1. Home
  2. T 0586/16 23-01-2018
Facebook X Linkedin Email

T 0586/16 23-01-2018

European Case Law Identifier
ECLI:EP:BA:2018:T058616.20180123
Date of decision
23 January 2018
Case number
T 0586/16
Petition for review of
-
Application number
02738145.8
IPC class
A23L 1/29
A23L 1/305
A23C 9/20
A61K 38/00
A61K 38/01
Language of proceedings
EN
Distribution
NO DISTRIBUTION (D)

Download and more information:

Decision in EN 447.65 KB
Documentation of the appeal procedure can be found in the European Patent Register
Bibliographic information is available in:
EN
Versions
Unpublished
Application title

CALORICALLY DENSE LIQUID ORAL SUPPLEMENT

Applicant name
Nestec S.A.
Opponent name

Fresenius Kabi Deutschland GmbH

N.V. Nutricia

Board
3.3.09
Headnote
-
Relevant legal provisions
European Patent Convention Art 100(c)
Keywords

Grounds for opposition - subject-matter extends beyond content of earlier application (yes)

Admissibility of late-filed documents

Catchword
-
Cited decisions
-
Citing decisions
T 0240/16
T 0815/22

I. This decision concerns the appeal filed by the proprietor of European patent No. 1 401 293 against the decision of the opposition division to revoke it.

II. With their notices of opposition the two opponents had requested revocation of the patent in its entirety on the grounds under Article 100(a) (lack of novelty and inventive step), (b) and (c) EPC.

The documents submitted during the opposition proceedings included:

D2: US 5,904,948 A; and

D15: "Enteral Nutrition Formulas (Systemic)" in Drug

Information Online from Drugs.com, revised on

8 March 1995, pages 1 to 35.

III. The main request before the opposition division contained two independent claims 1 and 2 as follows:

"1. A liquid oral supplement comprising:

a protein source that provides 14% to 20% of the total caloric content of the product, the protein source consisting of caseinate and a soy protein isolate wherein the caseinate and soy protein isolate are present at a ratio of 75:25 to 50:50;

a fat source providing at least 40% of the caloric content;

a carbohydrate source providing at least 25% of the caloric content; and the product having a caloric density of at least 9.42 kJ per ml (2.25 calories per ml),

which product is for use as a medicament for providing nutritional support to; [sic]

(a) a stressed individual;

(b) a malnourished individual; or

(c) an elderly individual."

"2. Use of a liquid oral supplement comprising:

a protein source that provides 14% to 20% of the total caloric content of the product, the protein source consisting of caseinate and a soy protein isolate wherein the caseinate and soy protein isolate are present at a ratio of 75:25 to 50:50;

a fat source providing at least 40% of the caloric content;

a carbohydrate source providing at least 25% of the caloric content;

and the product having a caloric density of at least 9.42 kJ per ml (2.25 calories per ml), for the manufacture of a medicament for providing nutritional support to; [sic]

(a) a stressed individual;

(b) a malnourished individual; or

(c) an elderly individual."

The opposition division rejected the main request, since the term "medicament" in claims 1 and 2 did not have a basis in the application as filed.

Auxiliary request 1 (not relevant to the present decision) was not admitted into the proceedings.

Claims 1 and 2 of auxiliary request 2 read as follows (amendments with respect to the corresponding claims of the main request highlighted):

"1. A liquid oral supplement comprising:

a protein source that provides 14% to 20% of the total caloric content of the product, the protein source consisting of caseinate and a soy protein isolate wherein the caseinate and soy protein isolate are present at a ratio of 75:25 to 50:50;

a fat source providing at least 40% of the caloric content;

a carbohydrate source providing at least 25% of the caloric content; and the product having a caloric density of at least 9.42 kJ per ml (2.25 calories per ml),

which product is for use as a medicament for providing nutritional support to; [sic]

[deleted: (a) a stressed individual;]

[deleted: (b)] a malnourished individual[deleted: ; or]

[deleted: (c) an elderly individual]."

"2. Use of a liquid oral supplement comprising:

a protein source that provides 14% to 20% of the total caloric content of the product, the protein source consisting of caseinate and a soy protein isolate wherein the caseinate and soy protein isolate are present at a ratio of 75:25 to 50:50;

a fat source providing at least 40% of the caloric content;

a carbohydrate source providing at least 25% of the caloric content;

and the product having a caloric density of at least 9.42 kJ per ml (2.25 calories per ml), for the manufacture of a medicament for providing nutritional support to; [sic]

[deleted: (a) a stressed individual;]

[deleted: (b)] a malnourished individual[deleted: ; or]

[deleted: (c) an elderly individual]."

The opposition division did not admit auxiliary request 2 into the proceedings. The restriction to malnourished individuals did not overcome the objection under Article 123(2) EPC. Hence, the amendment in auxiliary request 2 was also not "prima facie relevant".

Claims 1 and 2 of auxiliary requests 3 to 6 (annexed to the opposition division's decision as auxiliary requests 1 to 4) all included the same formulation based on the term "medicament" as in the corresponding claims of the main request. Hence, for the same reasons as for the main request, these claims did not have a basis in the application as filed.

IV. This decision was appealed by the proprietor (hereinafter: the appellant). The statement setting out the grounds of appeal contained a main request and auxiliary requests 1 to 5 as well as

D28: Excerpt from ICD 10-2016 "International

Statistical Classification of Diseases and

Related Health Problems 10th Revision (ICD-10)-

WHO Version for ;2016" [sic], Chapter IV

"Endocrine, nutritional and metabolic diseases

(E00-E90) Malnutrition (E40-E46)", 3 pages.

V. A response was filed by opponents 1 and 2 (hereinafter: respondents 1 and 2), that of respondent 1 containing

D29: Excerpt from Wikipedia "Overnutrition", 1 page.

VI. In its communication dated 16 August 2017 the board communicated its preliminary opinion to the parties.

VII. With its letter dated 29 November 2017 respondent 2 submitted:

D30: Definition of "malnutrition" from the

Cambridge Advanced Learner's Dictionary

& Thesaurus, 1 page;

D31: Excerpts from The Free Dictionary, Free

Thesaurus.com and Medical dictionary on the

term "malnutrition", 14 pages;

D32a: Letter of Mr Rupp, dated 7 April 2017; and

D32b: Excerpt from Oxford Dictionaries on the term

"malnutrition".

VIII. With its letter dated 13 December 2017 respondent 1 filed the following documents:

D28a/R1: "International statistical classification of

diseases and related health problems",

10th revision, volume 2,

5th edition, 2016, World Health

Organization, pages iii to vi and 1, 3 to 5

and 39; and

D28b/R1: Excerpt http://apps.who.int/classification/

icd10/browse/2016/en#/E86, 1 page.

IX. With its letter dated 19 December 2017 the appellant withdrew auxiliary request 2 filed with the statement of grounds of appeal, renamed auxiliary request 3 filed with the same letter as auxiliary request 2 and filed a new auxiliary request 3 together with:

D28a: Excerpt http://apps.who.int/classifications/

apps/icd/icd10online2003/fr-icd.htm, 1 page;

D28b: "Official Updates To ICD-10" from the Update

Reference Committee of the World Health

Organization, 30 November 2001, pages 1 to 7;

D28c: "Official Updates To ICD-10" from the Update

Reference Committee of the World Health

Organization, 30 November 2002, pages 1 to 7;

D28d: "Official Updates To ICD-10" from the Update

Reference Committee of the World Health

Organization, 11 February 2004, pages 1 to 11;

D33: "Nutritional Support", from Medline Plus,

5 pages;

D34a: "Guidelines On Artificial Nutrition

Support", 6 pages;

D34b: "Guidelines for Enteral Feeding in Adult

Hospital Patients", 1 page;

D35: W. W. Souba, "Nutritional Support", The New

England Journal of Medicine, volume 336,

number 1, January 1997, pages 41 to 48;

D36: S. Klein et al., "Nutrition Support in Clinical

Practice: Review of Published Data and

Recommendations for Future Research

Directions", Am. J. Clin. Nutr., volume 66,

1997, pages 683 to 706.

X. With its letter dated 9 January 2018 the appellant submitted

D37: The Merck Manual of Diagnosis and Therapy,

M. H. Beers at al. (ed.), 17th edition, Merck

Research Laboratories, Whitehouse Station N.J.

1999, pages 1 to 21.

XI. With its letter dated 12 January 2018 respondent 1 submitted:

D38: Excerpt from Wikipedia on the term "Food",

11 pages;

D39: L. Valentini et al., e-SPEN Journal, volume 9,

2014, pages e97 to e108;

D40: "Campbell's**(®) Souper Soups - Give Your Residents

More Than Just A Bowl Of Soup", 4 pages;

D41: EP 2 709 467 B1;

D42: WO 2013/102873 A2; and

D43: WO 2013/068425 A1.

XII. On 23 January 2018, oral proceedings were held before the board.

XIII. Claims 1 and 2 of the main request and auxiliary request 2 are identical to claims 1 and 2 of the main request and auxiliary request 2 before the opposition division (see point III above).

Claims 1 and 2 of auxiliary request 1 read as follows (amendments to the corresponding claims of the main request highlighted by the board):

"1. A liquid oral supplement comprising:

a protein source that provides 14% to 20% of the total caloric content of the product, the protein source consisting of caseinate and a soy protein isolate wherein the caseinate and soy protein isolate are present at a ratio of 75:25 to 50:50;

a fat source providing at least 40% of the caloric content;

a carbohydrate source providing at least 25% of the caloric content; and the product having a caloric density of at least 9.42 kJ per ml (2.25 calories per ml),

which product is for use as a medicament for providing nutritional support to[deleted: ;] an individual requiring nutritional support, whereby the individual is selected from:

(a) a stressed individual;

(b) a malnourished individual; or

(c) an elderly individual."

"2. Use of a liquid oral supplement comprising:

a protein source that provides 14% to 20% of the total caloric content of the product, the protein source consisting of caseinate and a soy protein isolate wherein the caseinate and soy protein isolate are present at a ratio of 75:25 to 50:50;

a fat source providing at least 40% of the caloric content;

a carbohydrate source providing at least 25% of the caloric content;

and the product having a caloric density of at least 9.42 kJ per ml (2.25 calories per ml), for the manufacture of a medicament for providing nutritional support to[deleted: ;] an individual requiring nutritional support, whereby the individual is selected from; [sic]

(a) a stressed individual;

(b) a malnourished individual; or

(c) an elderly individual."

Claims 1 and 2 of auxiliary request 3 read as follows (amendments to the corresponding claims of the main request highlighted by the board):

"1. A liquid oral supplement comprising:

a protein source that provides 14% to 20% of the total caloric content of the product, the protein source consisting of caseinate and a soy protein isolate wherein the caseinate and soy protein isolate are present at a ratio of 75:25 to 50:50;

a fat source providing at least 40% of the caloric content;

a carbohydrate source providing at least 25% of the caloric content; and the product having a caloric density of at least 9.42 kJ per ml (2.25 calories per ml),

which product is for use as a medicament for providing nutritional support to[deleted: ; ][deleted: [sic] ]an individual requiring nutritional support, whereby the individual is

[deleted: (a) a stressed individual;]

[deleted: (b)] a malnourished individual[deleted: ; or]

[deleted: (c) an elderly individual]."

"2. Use of a liquid oral supplement comprising:

a protein source that provides 14% to 20% of the total caloric content of the product, the protein source consisting of caseinate and a soy protein isolate wherein the caseinate and soy protein isolate are present at a ratio of 75:25 to 50:50;

a fat source providing at least 40% of the caloric content;

a carbohydrate source providing at least 25% of the caloric content;

and the product having a caloric density of at least 9.42 kJ per ml (2.25 calories per ml), for the manufacture of a medicament for providing nutritional support to[deleted: ; ][deleted: [sic] ]an individual requiring nutritional support, whereby the individual is

[deleted: (a) a stressed individual;]

[deleted: (b)] a malnourished individual[deleted: ; or]

[deleted: (c) an elderly individual]."

Claims 1 and 2 of auxiliary request 4 read as follows (amendments to the corresponding claims of the main request highlighted by the board):

"1. A liquid oral supplement comprising:

a protein source that provides 14% to 20% of the total caloric content of the product, the protein source consisting of caseinate and a soy protein isolate wherein the caseinate and soy protein isolate are present at a ratio of 75:25 to 50:50;

a fat source providing at least 40% of the caloric content;

a carbohydrate source providing at least 25% of the caloric content; and the product having a caloric density of at least 9.42 kJ per ml (2.25 calories per ml) and a sufficiently low viscosity to allow it to be administered by tube feeding,

which product is for use as a medicament for providing nutritional support to; [sic]

(a) a stressed individual;

(b) a malnourished individual; or

(c) an elderly individual."

"2. Use of a liquid oral supplement comprising:

a protein source that provides 14% to 20% of the total caloric content of the product, the protein source consisting of caseinate and a soy protein isolate wherein the caseinate and soy protein isolate are present at a ratio of 75:25 to 50:50;

a fat source providing at least 40% of the caloric content;

a carbohydrate source providing at least 25% of the caloric content;

and the product having a caloric density of at least 9.42 kJ per ml (2.25 calories per ml) and a sufficiently low viscosity to allow it to be administered by tube feeding, for the manufacture of a medicament for providing nutritional support to; [sic]

(a) a stressed individual;

(b) a malnourished individual; or

(c) an elderly individual."

Claims 1 and 2 of auxiliary request 5 read as follows (amendments to the corresponding claims of the main request highlighted by the board):

"1. A liquid oral supplement comprising:

a protein source that provides [deleted: 14% to 20%] 15% to 17% of the total caloric content of the product, the protein source consisting of caseinate and a soy protein isolate wherein the caseinate and soy protein isolate are present at a ratio of 75:25 to 50:50;

a fat source providing at least 40% of the caloric content;

a carbohydrate source providing at least 25% of the caloric content; and the product having a caloric density of at least 9.42 kJ per ml (2.25 calories per ml),

which product is for use as a medicament for providing nutritional support to; [sic]

(a) a stressed individual;

(b) a malnourished individual; or

(c) an elderly individual."

"2. Use of a liquid oral supplement comprising:

a protein source that provides [deleted: 14% to 20%] 15 to 17% of the total caloric content of the product, the protein source consisting of caseinate and a soy protein isolate wherein the caseinate and soy protein isolate are present at a ratio of 75:25 to 50:50;

a fat source providing at least 40% of the caloric content;

a carbohydrate source providing at least 25% of the caloric content;

and the product having a caloric density of at least 9.42 kJ per ml (2.25 calories per ml), for the manufacture of a medicament for providing nutritional support to; [sic]

(a) a stressed individual;

(b) a malnourished individual; or

(c) an elderly individual."

XIV. The appellant's arguments which are relevant to the present decision may be summarised as follows:

Main request

D28 and D28a to D28d should be admitted into the proceedings, since D28 was a timely reaction to the opposition division's change of mind during the oral proceedings and D28a to D28d were a timely reaction to respondent 1's argument that D28 had been post-published. Furthermore D33, D34a, D34b and D35 to D37 should be admitted into the proceedings. They were not so complex that respondent 1 did not have enough time to react to them before the oral proceedings.

The application as filed disclosed the provision of nutritional support. The provision of nutritional support implied a therapeutic intervention to provide nutrition to individuals who were not able to feed themselves and so were at risk of or were suffering from malnutrition. Such therapeutic treatment implied that the liquid oral supplement was a medicament. In the context of the application as filed, even just eating ordinary food was a therapeutic treatment, since it served to treat the clinical condition of malnutrition. If not treated, such a condition would lead to the death of the individual. The argument that providing nutritional support was a therapeutic treatment was supported by D2, D15, D33, D34a, D34b, D35, D36 and D37.

Auxiliary request 1

Auxiliary request 1 should be admitted into the proceedings since it was a timely reaction to the opposition division's change of mind during the oral proceedings as regards the compliance of the main request with Article 123(2) EPC.

Contrary to the respondents' assertion, the feature of an individual requiring nutritional support was clear. The skilled person would have been able to identify such individuals and would have known that they were not people who were just hungry.

The individuals in claims 1 and 2 were now restricted to those requiring nutritional support in order to treat or avoid the undesirable clinical condition of malnutrition. Hence individuals for whom the application as filed did not disclose any therapeutic treatment were no longer covered.

Auxiliary request 2

The opposition division's decision not to admit this request should be set aside. The opposition division should have admitted it, since it was a timely reaction to the opposition division's change of mind during the oral proceedings.

The use as a medicament in claim 1 and the manufacture of a medicament in claim 2 of auxiliary request 2 for providing nutritional support to a malnourished individual were based on the application as filed. As evidenced by D28, malnutrition was a specific entity in the International Statistical Classification of Diseases and Related Health Problems of the World Health Organization. Hence, the treatment of malnourished individuals as disclosed in the application as filed implied therapy and thus use as a medicament.

XV. The respondents' arguments which are relevant to the present decision may be summarised as follows:

Main request

D28 and D28a to D28d should not be admitted into the proceedings, since D28 was post-published and thus not prima facie relevant. Furthermore, D33, D34a, D34b and D35 to D37 should not be admitted into the proceedings, since they were so complex that it had not been possible to properly react to them prior to the oral proceedings. In particular, D37 was an excerpt from a book of several hundred pages, and it would have been necessary to read the entire book, including its chapter 5 referred to on page 10 of D37, to understand what it was saying about providing nutritional support.

Contrary to the appellant's assertion, the disclosure of providing nutritional support in the application as filed did not provide a basis for the use as and manufacture of a medicament in claims 1 and 2 of the main request. As shown by D38 to D43, the provision of nutritional support covered eating ordinary food without any effect extending beyond that obtained with ordinary food. Applying the appellant's understanding of the provision of nutritional support would mean that feeding a newborn baby with an infant formula was therapeutic, which did not make sense.

Auxiliary request 1

Auxiliary request 1 should not be admitted into the proceedings since it could have been filed before the opposition division and could not overcome the objection under Article 100(c) EPC raised against the main request.

The feature "an individual requiring nutritional support" inserted in claims 1 and 2 of auxiliary request 1 was unclear. Furthermore, it did not change the finding in respect of Article 100(c) EPC made with regard to the main request.

Auxiliary request 2

The opposition division's decision not to admit auxiliary request 2 was non-objectionable and thus should be maintained.

In the same way as for the main request, the provision of nutrition to malnourished individuals as disclosed in the application as filed did not extend beyond ordinary nutrition. Therefore, the ground under Article 100(c) EPC also prejudiced the maintenance of the patent on the basis of this auxiliary request.

Auxiliary requests 3 to 5

In the same way as for the main request and auxiliary requests 1 and 2, the ground under Article 100(c) EPC also prejudiced the maintenance of the patent on the basis of these auxiliary requests.

XVI. The appellant requested that the decision under appeal be set aside and that the case be remitted to the opposition division for examination of the remaining grounds for opposition (i.e. Article 100(a) and (b) EPC) in respect of the claims of

- either the main request or auxiliary request 1 filed with letter dated 27 April 2016;

- auxiliary request 2 filed as "auxiliary request 3" with letter dated 27 April 2016;

- auxiliary request 3 filed with letter dated 19 December 2017; or

- either of auxiliary requests 4 and 5 filed with letter dated 27 April 2016.

XVII. The respondents requested that the appeal be dismissed.

Respondent 1 furthermore requested that D28, D28a to d, D33, D34a, D34b, D35, D36 and D37 as filed by the appellant not be admitted into the proceedings.

The respondents furthermore requested that

- auxiliary request 1 not be admitted into the proceedings;

- auxiliary request 2 not be admitted into the proceedings, implying that the opposition division's decision not to admit auxiliary request 2 be maintained.

Lastly the respondents requested that, should the board consider the amendments in any of the appellant's claim requests to meet the objections under Article 123(2) EPC as well as the further objections, the case be remitted to the opposition division for discussion of Articles 83, 54 and 56 EPC.

Main request

1. Admittance of documents

1.1 Respondent 1 requested that D28, D28a to D28d, D33, D34a, D34b, D35, D36 and D37 not be admitted into the proceedings.

1.2 D28 was filed by the appellant with its statement of grounds of appeal. Respondent 1 argued that D28 should not be admitted, since it was post-published and thus not relevant.

In its preliminary opinion the opposition division had stated that the main request was not in breach of Article 123(2) EPC. It was only during the oral proceedings that it changed its mind and rejected the main request for not being based on the application as filed. The appellant filed D28 to address the question of how the skilled person would understand the application as filed. Its filing with the statement of grounds of appeal is a timely reaction to the opposition division's change of mind. The board therefore decided to reject the request not to admit D28 into the proceedings.

1.3 D28a to D28d were submitted by the appellant with its letter dated 19 December 2017. They were filed in order to address the question of when the content of D28 had become public. They are thus a timely response to respondent 1's objection that D28 had been post-published. The board therefore decided to reject the request not to admit D28a to D28d into the proceedings.

1.4 D33, D34a, D34b, D35 and D36 were filed with the appellant's letter dated 19 December 2017. Respondent 1 argued that these documents should not be admitted into the proceedings, since they were rather complex and there had not been enough time before the opposition division to study and react to them.

Respondent 1 did not explain why the documents were so complex that the time remaining until the oral proceedings was not enough to study them. In fact these documents are fairly short and relatively easy to understand. The board therefore decided to reject the request not to admit these documents into the proceedings.

1.5 For D37, the admissibility of which was also contested by respondent 1, the situation is different. It was filed with the appellant's letter dated 9 January 2018, i.e. just two weeks prior to the oral proceedings, to address the question of what was meant by the provision of nutritional support. As acknowledged by the appellant, this document is an excerpt from a book of several hundred pages. In order to see what this book is saying as regards the provision of nutritional support, it is not enough to read only the few pages contained in D37. On the contrary, it would have been necessary to read the book in its entirety, and in particular chapter 5, explicitly referred to on page 10 of D37. Since the short time that remained until the oral proceedings was not enough to do so, the board decided not to admit D37 into the proceedings.

2. Amendments - Article 100(c) EPC

2.1 Claim 1 is directed to a liquid oral supplement for use as a medicament for providing nutritional support to a stressed individual, a malnourished individual or an elderly individual. Claim 2 is directed to the use of a liquid oral supplement for the manufacture of a medicament for providing nutritional support to a stressed individual, a malnourished individual or an elderly individual.

2.2 It was a matter of dispute between the parties whether the use as a medicament in claim 1 and the manufacture of a medicament in claim 2 of the main request were based on the application as filed.

2.3 The appellant acknowledged that the application as filed did not contain any explicit disclosure of the use or manufacture of a medicament. The appellant argued however that this use or manufacture was implicitly disclosed in the application as filed. More specifically, the application as filed disclosed the provision of nutritional support, and this implied a therapeutic intervention to provide nutrition to individuals who were not able to feed themselves and so were at risk of or were suffering from malnutrition. Such therapeutic treatment implied that the liquid oral supplement was a medicament.

2.4 The board acknowledges that the application as filed (e.g. page 2, lines 28 to 30) discloses the provision of nutritional support. The question with regard to Article 100(c) EPC is therefore whether the skilled person using his common general knowledge would directly and unambiguously derive from the application as filed that this provision of nutritional support is a therapeutic treatment.

2.4.1 According to the Wikipedia excerpt D38, providing nutritional support merely means the consumption of food. According to the scientific article D39, which tries to give suggestions for terminology in the field of clinical nutrition (title), nutritional support is the provision of nutrition or nutrients either orally (regular diet, therapeutic diet, fortified food, oral nutritional supplements) or via enteral nutrition or parenteral nutrition to prevent or treat disease-related malnutrition (point 1.8 on page e100). Furthermore, D40 discloses soups for elderly individuals as nutritional support, defines the goal of nutritional support as nutritional repletion and improved quality of life and refers in this context to the process of eating as fulfilling a physiological and psychological need (second page of D40).

In view of the above, the provision of nutritional support at the very least covers ordinary nutrition.

This understanding in fact has been applied by the appellant itself in its patent D41 and patent applications D42 and D43. In paragraph [0003] of D41, it states that the goal of nutritional support is to provide nutritional products that can very efficiently provide individuals with a delicious, healthy and nutritious bite-sized snack, while at the same time providing a snack product that is easy to consume. In paragraph [0004] of D42, it states that one goal of nutritional support is to provide athletes with appropriate nutritional compositions that meet their nutritional requirements for high-intensity workouts without causing negative side-effects or loss of active compounds. And on page 5, lines 12 to 13, of D43, providing nutritional support is mentioned in the context of the consumption of nutrients from food ingredients of natural origin.

2.4.2 The board acknowledges that ordinary nutrition is needed for nutritional repletion and thereby for maintaining the body's principal functions and that without eating one dies of starvation. The board is however convinced that this effect, which is intrinsically linked with eating, is not necessarily a therapeutic one. Otherwise every mother feeding her newborn baby with an infant formula would be carrying out a therapeutic step, which in the board's view would take the definition of therapeutic treatment too far. In the same way, the provision of nutritional support to malnourished individuals is not necessarily a therapeutic treatment, since it may merely include the normal process of eating in order to fulfill the individual's physiological and psychological needs.

2.4.3 This is not changed by D2, D15, D28, D34a, D34b, D35 and D36, referred to by the appellant. More specifically, none of these documents discloses any effect obtained by the provision of nutritional support that extends beyond that obtained by ordinary nutrition. Furthermore, D15, D34a, D34b, D35 and D36 do not refer to the provision of nutritional support as disclosed in the application as filed (D34a: artificial nutritional support; D15 and D34b: enteral nutrition; D35: feeding via the enteral or intravenous route; D36: feeding via the enteral, intravenous and parenteral route). These documents thus have no relevance to what the skilled person would understand by the provision of nutritional support.

2.4.4 Therefore, the provision of nutritional support as disclosed in the application as filed includes ordinary nutrition, which is not a therapeutic treatment.

2.4.5 The board is aware in this respect that according to D33 providing nutritional support "is therapy for people who cannot get enough nourishment by eating and drinking" and that the nutritional support is provided through a needle or catheter placed in a patient's vein or a feeding tube which goes into the stomach. D33 is however in contradiction with e.g. D38 to D40, which, as set out above, define the provision of nutritional support simply as the provision of food (D38), a regular diet (D39) or soups (D40). So, at the very least there is no commonly accepted understanding that the provision of nutritional support as disclosed in the application as filed is a therapeutic treatment.

2.5 In view of the above, the skilled person, even taking his common general knowledge into account, would not directly and unambiguously derive from the application as filed that the provision of nutritional support disclosed therein was a therapeutic treatment. Consequently, the use as and manufacture of a medicament in claims 1 and 2 are not based on the application as filed. The ground under Article 100(c) EPC thus prejudices the maintenance of the patent in the form of the main request.

Auxiliary request 1

3. Admissibility

Both respondents requested that auxiliary request 1 not be admitted into the proceedings. The filing of auxiliary request 1 can be considered a timely reaction to the opposition division's change of mind during the oral proceedings (see point 1.2 above). Therefore, the board decided to admit auxiliary request 1 into the proceedings.

4. Amendments - Article 100(c) EPC

4.1 Auxiliary request 1 differs from the main request in that in claims 1 and 2 the individuals are defined as requiring nutritional support. As set out above in point 2.4.2 for the main request, even for individuals requiring nutritional support, such as newborn babies, the application as filed does not disclose anything which goes beyond ordinary nutrition. Therefore, for the same reasons as given above with regard to the main request, claims 1 and 2 of auxiliary request 1 are not based on the application as filed. Thus the ground under Article 100(c) EPC also prejudices the maintenance of the patent in the form of auxiliary request 1.

Auxiliary request 2

5. Admissibility

The opposition division decided not to admit this request ("auxiliary request 2" before the opposition division). The respondents requested that this decision be maintained.

The opposition division did not admit auxiliary request 2 since it was not prima facie allowable. The board acknowledges that prima facie allowability is normally the correct criterion to be applied when deciding on admittance of a late-filed claim request. However, in the present case the opposition division should have taken into account its change of mind during the oral proceedings (see point 1.2 above) and should have admitted the then auxiliary request 2, since it was a reaction thereto.

The board therefore decided to set aside the opposition division's decision as regards admittance of auxiliary request 2 and admitted this auxiliary request into the proceedings.

6. Amendments - Article 100(c) EPC

6.1 Claims 1 and 2 of auxiliary request 2 differ from claims 1 and 2 of the main request in that the two alternatives of a stressed and an elderly individual have been deleted. The individual is thus restricted to a malnourished individual.

As set out above in point 2.4.2 for the main request, even for malnourished individuals the application as filed does not disclose any therapeutic treatment. Therefore, for the same reasons as given above with regard to claims 1 and 2 of the main request, claims 1 and 2 of auxiliary request 2 are not based on the application as filed. Thus the ground under Article 100(c) EPC also prejudices the maintenance of the patent in the form of auxiliary request 2.

Auxiliary request 3

Auxiliary request 3 is a combination of auxiliary requests 1 and 2. As not disputed by the appellant during the oral proceedings, the board's finding with regard to auxiliary requests 1 and 2 equally applies to auxiliary request 3. Thus the ground under Article 100(c) EPC also prejudices the maintenance of the patent in the form of auxiliary request 3.

Auxiliary requests 4 and 5

7. Claims 1 and 2 of auxiliary request 4 differ from claims 1 and 2 of the main request in that the product defined in these claims must have a "sufficiently low viscosity to allow it to be administered by tube feeding".

Claims 1 and 2 of auxiliary request 5 differ from claims 1 and 2 of the main request by a more restricted range for the amount of protein source.

The appellant itself acknowledged that these auxiliary requests had only been filed to meet potential objections with regard to inventive step and that they did not overcome the objection under Article 100(c) EPC raised against the main request. Accordingly, the ground under Article 100(c) EPC also prejudices the maintenance of the patent in the form of auxiliary requests 4 and 5.

Request for remittal

In view of the above finding that none of the appellant's claim requests is allowable, the board did not need to decide on the request for remitting the case to the opposition division.

Order

For these reasons it is decided that:

The appeal is dismissed.

Footer - Service & support
  • Service & support
    • Website updates
    • Availability of online services
    • FAQ
    • Publications
    • Procedural communications
    • Contact us
    • Subscription centre
    • Official holidays
    • Glossary
Footer - More links
  • Jobs & careers
  • Press centre
  • Single Access Portal
  • Procurement
  • Boards of Appeal
Facebook
European Patent Office
EPO Jobs
Instagram
EuropeanPatentOffice
Linkedin
European Patent Office
EPO Jobs
EPO Procurement
X (formerly Twitter)
EPOorg
EPOjobs
Youtube
TheEPO
Footer
  • Legal notice
  • Terms of use
  • Data protection and privacy
  • Accessibility